Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Receivables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Change in Receivables for 6 consecutive years, with -$196000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 60.32% to -$196000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$196000.0, a 57.21% increase, with the full-year FY2025 number at -$196000.0, up 57.21% from a year prior.
  • Change in Receivables was -$196000.0 for Q4 2025 at Caribou Biosciences, down from -$129000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q4 2022 to a low of -$2.2 million in Q3 2022.
  • A 5-year average of -$32800.0 and a median of -$74000.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 1024.32% in 2022; the steepest drop was 1674.32% in 2022.
  • Caribou Biosciences' Change in Receivables stood at $575000.0 in 2021, then surged by 218.61% to $1.8 million in 2022, then tumbled by 110.04% to -$184000.0 in 2023, then plummeted by 168.48% to -$494000.0 in 2024, then surged by 60.32% to -$196000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Change in Receivables are -$196000.0 (Q4 2025), -$129000.0 (Q3 2025), and $112000.0 (Q2 2025).